Read about the latest breakthroughs, awards and ongoing work from the SGC. Discover how our work is making a global impact and driving forward the field of drug discovery. Interested in getting first the latest news from SGC?
GlaxoSmithKline has developed a potent, selective, cell-active EZH2 inhibitor, GSK343, and has made this available as a chemical probe as part of the SGC epigenetics initiative. The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and…
The Pfizer-SGC project aims to tackle a rare, hereditary metabolic disorder called homocystinuria, which leaves patients unable to metabolise the amino acid methionine. A team of researchers at Pfizer Rare Disease unit will work with Dr Wyatt Yue at the Structural Genomics Consortium at the…
Researchers from Oxford University, GlaxoSmithKline and Cellzome, as well as Memorial Sloan Kettering Hospital have developed and characterised the first selective inhibitor for a specific class of histone demethylases and demonstrated its utility in inhibiting proinflammatory cytokine…
Categories